Medication info
Metwon Sustained-Release Tablet (Metformin Hydrochloride)

Metwon Sustained-Release Tablet (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Palmgen Science Co., Ltd.
Appearance
White rectangular tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201502718 · Approved 2015.04.30 · Insurance code 670103780

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on drug efficacy and tolerability and should not exceed the recommended maximum daily dose. - The usual starting dose is metformin hydrochloride extended-release tablets 500mg once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose escalation. The maximum dose is 2000mg per day. - When increasing the dose, increase it by 500mg each week; up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with up to 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess the response to treatment with this medicine and determine the minimum effective dose. Glycated hemoglobin levels should be measured at approximately 3-month intervals. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, respectively, administration of this medicine must be discontinued immediately.

Ingredients

Manufacturer
Palmgen Science Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes
  • poor blood sugar control
  • overweight
View approved original text

This medication is used for blood sugar control in adult patients with type 2 diabetes, particularly those who are overweight, when diet and exercise alone are insufficient. It is effective as monotherapy and can enhance treatment effects when used in combination with other oral hypoglycemic agents or insulin. This drug helps improve blood sugar levels and aids in diabetes management.

How to take

Adult dose

The dose should be determined individually based on drug efficacy and tolerability and should not exceed the recommended maximum daily dose. - The usual starting dose is metformin hydrochloride extended-release tablets 500mg once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose escalation. The maximum dose is 2000mg per day. - When increasing the dose, increase it by 500mg each week; up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with up to 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess the response to treatment with this medicine and determine the minimum effective dose. Glycated hemoglobin levels should be measured at approximately 3-month intervals. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, respectively, administration of this medicine must be discontinued immediately.

Precautions

This drug can rarely cause a serious metabolic complication called lactic acidosis, which can be life-threatening, so patients should be alert for symptoms. When used in conjunction with other diabetes medications, there is a risk of hypoglycemia, and blood sugar levels should be carefully monitored. It should not be given to patients with moderate to severe renal impairment, dehydration, acute severe infections, or certain acute conditions such as heart failure. Administration should be temporarily paused before and after tests using iodinated contrast agents, verifying renal function before resuming. It should not be used in patients with hypersensitivity to any component of this drug or in those with type 1 diabetes or diabetic ketoacidosis. Administration should be temporarily stopped during severe infections, major trauma, or pre- and post-surgery, and resumed only after patient conditions improve. Patients with poor nutritional status or liver dysfunction, or excessive alcohol consumption need to use with caution. During pregnancy, especially when there is a risk of placental insufficiency or preeclampsia, use should be avoided. Gastrointestinal disturbances may occur frequently, so it is recommended to start at a lower dose and gradually increase it, taking with meals. Vitamin B12 deficiency may occur, so regular blood tests should be conducted for monitoring. If renal function declines, the risk of accumulation and side effects of this drug increases, hence regular renal function tests are essential. Symptoms of hypoglycemia are rare with monotherapy, but the risk of hypoglycemia increases when used with other hypoglycemic agents or alcohol. Patients should avoid excessive alcohol consumption while taking this medication and consult healthcare professionals immediately if sudden blood sugar changes or abnormal symptoms occur. Older adults are at higher risk of renal function decline and require dose adjustment and regular monitoring, ensuring not to exceed the maximum dosage. This drug should be swallowed whole and not chewed or crushed; the tablet coating may be excreted, which is normal. It can interact with other medications, so patients should inform healthcare professionals of any other medications being taken, and blood sugar and renal function should be checked periodically. Blood sugar control is crucial during pregnancy, and this drug can be used alone or as a substitute with insulin if necessary, but should be under the guidance of a physician as it may affect fetal growth. During breastfeeding, this drug is excreted in breast milk, so careful decision-making regarding breastfeeding and medication discontinuation is required. It is not recommended for children or adolescents under 17 years due to the lack of established safety and efficacy. In case of overdose, while hypoglycemia is rare, there is a risk of lactic acidosis, and immediate medical treatment should be sought; dialysis may be helpful if necessary. This drug has not been reported to have carcinogenic or mutagenic potential even with long-term use and helps control blood sugar without weight gain. This medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste disturbance
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • itching
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly closed container to protect it from air and moisture. The recommended storage temperature is between 1 degree and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

White rectangular tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.